SCHEMBL6347635

SCHEMBL6347635

CC(=O)c1ccc(Oc2ccc3cc(OCc4ccccc4)ccc3c2)nc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.59
ALDH1A1 P00352 2/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ACACB O00763 3/20 0.50
ACACA Q13085 3/20 0.50
ALOX5 P09917 1/20 0.50
OPRM1 P35372 3/20 0.49
OPRD1 P41143 2/20 0.49
OPRK1 P41145 2/20 0.49
MRGPRX4 Q96LA9 1/20 0.49
NPC1 O15118 1/20 0.48
MAPT P10636 1/20 0.48
NR4A1 P22736 1/20 0.48
NR4A2 P43354 1/20 0.48
NR4A3 Q92570 1/20 0.48
LMNA P02545 1/20 0.47
GLA P06280 1/20 0.47
CASP3 P42574 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6346472 0.90 MAOB (0.69) MAOBALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL6416751 0.85 MAOB (0.52) MAOBALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL6337233 0.85 MAOB (0.55) MAOBALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL6338480 0.85 MAOB (0.73) MAOBALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL6341556 0.82 ALOX5 (0.51) ALDH1A1ACACBACACAALOX5OPRM1
SCHEMBL1091737 0.82 MAOB (0.62) MAOBALDH1A1HTTSMN1; SMN2L3MBTL1
SCHEMBL19405962 0.81 NR4A2 (0.62) MAOBSMN1; SMN2MRGPRX4NR4A1NR4A2
SCHEMBL19406082 0.80 MAOB (0.51) MAOBSMN1; SMN2ACACBACACAOPRM1
SCHEMBL6339254 0.80 NR4A2 (0.68) MAOBSMN1; SMN2ACACBACACAOPRM1
SCHEMBL13093866 0.79 HRH3 (0.56) ALDH1A1HTTACACBACACAOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1245380-C Anthranilic acid derivatives TEIJIN LTD (JP) 2006-03-15 CN disclosed
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 MAOB 2681/4885ALDH1A1 250/4885HTT 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.